This is a preview of subscription content, log in via an institution to check access.
References
Atkinson, A.B.; Lever, A.F.; Brown, J.J. and Robertson, J.J.S.: Combined treatment of severe intractable hypertension with captopril and diuretic. Lancet 2: 105–108 (1980).
Brunner, H.R.; Gavras, H.; Waeber, B. et al.: Clinical use of an orally acting converting enzyme inhibitor: Captopril. Hypertension 2: 558–566 (1980).
Ferguson, R.K.; Vlasses, P.H.; Koplin, J.R. et al.: Captopril in severe treatment resistant hypertension. American Heart Journal 99: 579–585 (1980).
Heel, R.C.; Brogden, R.N.; Speight, T.M. and Avery, G.S.: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–452 (1980).
Hollenberg, N.K.: Converting enzyme inhibition: Implications for renal perfusion and function. Clinical and Experimental Pharmacology and Physiology 7 (Suppl.): 73–79 (1982).
Johnston, C.I.; McGrath, B.P.; Matthews, P.G. and Jackson, B.: Treatment of hypertension with angiotensin converting enzyme inhibitors. Clinical and Experimental Pharmacology and Physiology 7 (Suppl.): 135–144 (1982).
Knill, J.B.: The development of captopril and its role in the treatment of hypertension. Clinical and Experimental Pharmacology and Physiology 7 (Suppl.): 63–72 (1982).
Lopez-Obejero, J.A.; Saal, J.; D’Angelo, W.A. et al.: Reversal of vascular and renal crises of scleroderma by oral angiotensin converting enzyme blockade. New England Journal of Medicine 300: 1417–1419 (1979).
Laragh, J.J.; Case, D.B.; Atlas, S.A. and Sealey, J.E.: Captopril compared with other antirenin system agents in hypertensive patients: Its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 2: 586–593 (1980).
McGrath, B.P.; Matthews, P.G. and Johnston, C.I.: Use of captopril in the diagnosis of renal hypertension. Australia and New Zealand Journal of Medicine 11: 359–363 (1981).
Ondetti, M.A.; Rubin, B. and Cushman, D.W.: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 196: 441–444 (1977).
Vaughan, E.D.; Carey, R.M.; Ayers, C.R. and Peach, M.J.: Haemodialysis-resistant hypertension: Control with an orally active inhibitor of angiotensin-converting enzyme. Journal of Clinical Endocrinology and Metabolism 48: 869–871 (1979).
Veterans’ Administration Co-operative Study Group on Antihypertensive Agents: Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. British Journal of Clinical Pharmacology 14: 975–1015 (1982).
Vidt, D.G.; Bravo, E.L. and Fouad, F.M.: Captopril. New England Journal of Medicine 306: 214–219 (1982).
Wauters, J.P.; Waeber, B.; Brunner, H.R. et al.: Uncontrollable hypertension in patients on hemodialysis: Long term treatment with captopril and salt subtraction. Clinical Nephrology 16: 86–92 (1981).
White, N.J.; Yahaja, H.; Rajapopalan, B. et al.: Captopril and frusemide in severe drug-resistant hypertension. Lancet 2: 108–110 (1980).
Zimmerman, B.G.: Adrenergic facilitation by angiotensin — does it serve a physiological function? Clinical Science 60: 343–348 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnston, C.I., Arnolda, L. & Hiwatari, M. Angiotensin-Converting Enzyme Inhibitors in the Treatment of Hypertension. Drugs 27, 271–277 (1984). https://doi.org/10.2165/00003495-198427030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198427030-00006